Advertisement
Singapore markets closed

  • Straits Times Index

    3,410.81
    -29.07 (-0.85%)
     

  • Nikkei

    40,912.37
    -1.28 (-0.00%)
     

  • Hang Seng

    17,799.61
    -228.67 (-1.27%)
     

  • FTSE 100

    8,203.93
    -37.33 (-0.45%)
     

  • Bitcoin USD

    57,658.63
    +1,289.10 (+2.29%)
     

  • CMC Crypto 200

    1,197.57
    -11.13 (-0.92%)
     

  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     

  • Dow

    39,375.87
    +67.87 (+0.17%)
     

  • Nasdaq

    18,352.76
    +164.46 (+0.90%)
     

  • Gold

    2,399.80
    +30.40 (+1.28%)
     

  • Crude Oil

    83.44
    -0.44 (-0.52%)
     

  • 10-Yr Bond

    4.2720
    -4.3550 (-50.48%)
     

  • FTSE Bursa Malaysia

    1,611.02
    -5.73 (-0.35%)
     

  • Jakarta Composite Index

    7,253.37
    +32.48 (+0.45%)
     

  • PSE Index

    6,492.75
    -14.74 (-0.23%)
     

China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants

Vandana Singh
·2-min read

Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) Beyfortus (nirsevimab), a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season.

Beyfortus will be available during the 2024-2025 RSV season.

Beyfortus is the first approved preventive option to protect against RSV in a broad infant population, including protecting those infants born healthy at term, preterm, or with specific health conditions that make them vulnerable to severe RSV disease.

ADVERTISEMENT

The approval is based on three Beyfortus pivotal late-stage clinical trials. Across all clinical endpoints, a single dose of Beyfortus demonstrated consistent efficacy against RSV lower respiratory tract disease (LRTD), extending through five months, the duration of a typical RSV season.

Beyfortus was approved in the European Union in October 2022 for the prevention of RSV LRTD in newborns and infants during their first RSV season and received approval by the FDA in July 2023 following the unanimous recommendation by the Antimicrobial Drugs Advisory Committee in June 2023.

In November, the U.S. Centers for Disease Control and Prevention (CDC) released more than 77,000 additional doses of Beyfortus (nirsevimab), a respiratory syncytial virus drug.

Price Action: AZN shares are down 0.85 at $66.77 during the premarket session on the last check Tuesday, and SNY stock closed at $49.73 on Friday.

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.